-

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Vanda Pharmaceuticals Inc. (VNDA)

SAN DIEGO & WASHINGTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) for breaches of fiduciary duties, unjust enrichment, and violations of the Securities Exchange Act of 1934. Vanda Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of central nervous system disorders.

If you suffered a loss as a result of Vanda's misconduct, click here.

Vanda Pharmaceuticals Used its Drugs for Off-Label Purposes

For years, Vanda and its officers hid that Vanda was involved in a fraudulent scheme that included violations of federal Medicare, Medicaid, and Tricare programs and that Vanda's promotional materials were false and misleading, garnering scrutiny from the FDA. Specifically, Vanda schemed to promote its drugs Fanapt and Hetlioz for "off-label" uses in addition to other prohibited promotional strategies. Vanda's executives and officers knew about the prohibited promotional strategies and actively participated in the fraudulent activity. Vanda also issued misleading statements regard tradipitant's clinical trials with the FDA. When the truth was revealed, Vanda's stock declined over 5% and has slipped even more, now trading at just around $11.00. As a result of this conduct, Vanda is facing significant liability from a Qui Tam lawsuit and has already incurred substantial expenses in its investigation. Vanda has also been named as a defendant in a securities class action lawsuit, causing further damage to the company.

Vanda Pharmaceuticals Inc. (VNDA) Shareholders Have Legal Options

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. For be notified if a class action against Vanda Pharmaceuticals settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Ardent Health, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ardent Health, Inc. (NYSE: ARDT) securities between July 18, 2025 and November 12, 2025. Ardent Health and its affiliates operate acute care hospitals and other healthcare facilities. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegati...

Investor Notice: Robbins LLP Informs Investors of the Varonis Systems, Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Varonis Systems, Inc. (NASDAQ: VRNS) securities between February 5, 2025 and October 28, 2025. Varonis is a global security company that provides software products and services to discovery and classify critical data, remediate exposures, and detect advanced threats with the help of AI-powered technologies. For more information, submit a form,...

Investor Notice: Robbins LLP Informs Investors of the Fermi Inc. Securities Class Action

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Fermi Inc. (NASDAQ: FRMI): (a) common stock pursuant to the registration statement issued in connection with the Company's October 2025 initial public offering ("IPO"); or (b) securities between October 25, 2025 and December 11, 2025. Fermi purports to be an energy and artificial intelligence (“AI”) infrastructure company. For more information...
Back to Newsroom